X4 Pharmaceuticals, Inc.XFORNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+242.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+242.2%/yr
vs -50.2%/yr prior
Acceleration
+292.4pp
Accelerating
Percentile
P97
Near historical high
vs 3Y Ago
40.1x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 44.19% |
| Q3 2025 | 6.95% |
| Q2 2025 | -141.76% |
| Q1 2025 | 62.52% |
| Q4 2024 | 3.05% |
| Q3 2024 | -12.40% |
| Q2 2024 | 9.88% |
| Q1 2024 | -21.08% |
| Q4 2023 | -33.22% |
| Q3 2023 | 2.79% |
| Q2 2023 | 19.19% |
| Q1 2023 | -38.86% |
| Q4 2022 | 1.10% |
| Q3 2022 | -4.50% |
| Q2 2022 | 8.68% |
| Q1 2022 | -6.17% |
| Q4 2021 | -34.07% |
| Q3 2021 | 25.97% |
| Q2 2021 | -4.08% |
| Q1 2021 | -5.37% |
| Q4 2020 | -22.17% |
| Q3 2020 | -25.04% |
| Q2 2020 | 26.20% |
| Q1 2020 | -68.02% |
| Q4 2019 | 27.65% |
| Q3 2019 | 10.64% |
| Q2 2019 | -21.63% |
| Q1 2019 | -65.82% |
| Q4 2018 | 13.16% |
| Q3 2018 | 39.47% |
| Q2 2018 | -10.70% |
| Q1 2018 | 5.66% |
| Q4 2017 | -153.58% |
| Q3 2017 | 20.01% |
| Q2 2017 | -81.23% |
| Q1 2017 | -11.04% |
| Q4 2016 | 0.00% |
| Q1 2016 | 0.00% |